Korean drugmaker Shinpoong Pharm said Côte d'Ivoire listed the company’s new anti-malarial drug Pyramax as the first-line treatment in the state guideline on Nov. 27.
Pyramax is the 16th locally developed novel drug. It is an artemisinin-based combination therapy that simultaneously treats tropical splenomegaly syndrome and vivax malaria.
Côte d’Ivoire’s health and welfare minister granted final approval for the treatment guideline. The country is expected to publish the guideline in the first half of 2019.
“It is unprecedented that a Korean pharmaceutical firm’s novel drug was listed as the first-line treatment in a country in Africa,” an official at Shinpoong Pharm said.
In August 2017, the World Health Organization (WHO) put Pyramax on its “Model List of Essential Medicines.”
Shinpoong Pharm rolled out Pyramax in seven countries, including Kenya and West Africa, in 2018. Earlier this year, the company began distributing the drug in the Cambodian public healthcare sector for over 30,000 patients.
Côte d'Ivoire’s 24.3 million population is exposed to the risk of malaria infection, and an average of 3.4 million people are diagnosed with malaria a year.
<© Korea Biomedical Review, All rights reserved.>